Other complications such as administration site disorder, anxiety, fatigue, headache, urinary tract infection (UTI) and diarrhea did not show a statistically significant risk in the GLP-1 agonists group compared to the control group (see Fig. 6). This evidence concerns the gene GLP1R and urinary tract infection.